Stockreport

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1' immune cell engager CB699 at AACR 2024 [Yahoo! Finance]

BioNTech SE - American Depositary Shares  (BNTX) 
PDF Preclinical data demonstrate strong rationale for ongoing Phase 1b POTENTIA trial investigating conditional CD137 (4-1BB) agonist CB307 as monotherapy and in combinatio [Read more]